Acumen Pharmaceuticals, Inc. business relationships
Companies named in Acumen Pharmaceuticals, Inc.’s 10-K filed 2026-03-26, and public companies whose annual reports name Acumen Pharmaceuticals, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 4 / 100 Top 6% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Acumen Pharmaceuticals, Inc.’s annual report 3
“During the collaboration, Merck developed sabirnetug, an ADDL antibody, and intellectual property related to sabirnetug was filed by Merck.” SEC filing
“In November 2023, we announced a global collaboration and license agreement with Halozyme, Inc., or Halozyme, to develop a subcutaneous formulation of sabirnetug.” SEC filing
“We entered into a single product license agreement with Lonza Sales AG, or Lonza, on November 2, 2022, for non-exclusive access to Lonza's glutamine synthetase gene expression system known as the GS System ® , to use, develop and manufacture sabirnetug.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.